Literature DB >> 12416680

Immunization with combined HSV-2 glycoproteins B2 : D2 gene DNAs: protection against lethal intravaginal challenges in mice.

Hyung Hoan Lee1, Soung Chul Cha, Dong June Jang, Jun Keun Lee, Dong Wan Choo, Young Sik Kim, Hong Sun Uh, Soo Young Kim.   

Abstract

The immunity of a combined DNA vaccine of HSV-2 glycoproteins B2 (gB2) and D2 (gD2) genes in comparison to individual vaccines was studied with regard to protecting against the HSV infection. Two recombinant DNA vaccines of the pHS2-gB2 or pHS2-gD2 were constructed and formulated. The neutralizing antibody titers appeared higher in the B2 : D2 gene cocktail-vaccinated mice than that of the individual B2 or D2 gene-vaccinated group alone, and the positive KOS control induced higher titer of the neutralizing antibody than combined or individual gene vaccines. The mock-immunized mice failed to induce enough. The ranks for the CTL activity and the protection rates against the lethal intravaginal challenge were shown as KOS > B2:D2 cocktail > D2 > B2 gene vaccines. The vaginal external diseases in the B2 : D2 or D-vaccinated mice were significantly reduced against the challenging dosages. The virus titers in the vaginal secretions of the vaccinated mice significantly reduced with time, and the B2 : D2 gene vaccine decreased more than each individual vaccine alone. It can be concluded that the cocktailed vaccines are more effective in the humoral and cellular immune responses in the mice, and in the protection of the mice against the intravaginal challenging dosages when compared with individual gene vaccines. All the DNA vaccines failed to block the latent infection in sensory nerves.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416680     DOI: 10.1023/a:1020113902834

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  32 in total

1.  Electron microscopy of herpes simplex virus. I. Entry.

Authors:  C Morgan; H M Rose; B Mednis
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

2.  Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain.

Authors:  R Ramakrishnan; D J Fink; G Jiang; P Desai; J C Glorioso; M Levine
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

3.  Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2.

Authors:  D Long; T J Madara; M Ponce de Leon; G H Cohen; P C Montgomery; R J Eisenberg
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.

Authors:  D Navarro; P Paz; L Pereira
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

6.  Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

7.  Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge.

Authors:  V Landolfi; C D Zarley; A S Abramovitz; N Figueroa; S L Wu; M Blasiak; S T Ishizaka; E M Mishkin
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Specificity of the immune response of mice to herpes simplex virus glycoproteins B and D constitutively expressed on L cell lines.

Authors:  B A Blacklaws; A A Nash; G Darby
Journal:  J Gen Virol       Date:  1987-04       Impact factor: 3.891

9.  Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.

Authors:  E Manickan; R J Rouse; Z Yu; W S Wire; B T Rouse
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

10.  Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.

Authors:  P W Berman; P E Vogt; T Gregory; L A Lasky; E R Kern
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

View more
  5 in total

1.  Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.

Authors:  Xingsheng Wang; Guangyan Xie; Jianming Liao; Dengke Yin; Wenyan Guan; Mingjie Pan; Jingnian Li; Yuexi Li
Journal:  Virol J       Date:  2011-05-16       Impact factor: 4.099

2.  Prediction and identification of potential immunodominant epitopes in glycoproteins B, C, E, G, and I of herpes simplex virus type 2.

Authors:  Mingjie Pan; Xingsheng Wang; Jianmin Liao; Dengke Yin; Suqin Li; Ying Pan; Yao Wang; Guangyan Xie; Shumin Zhang; Yuexi Li
Journal:  Clin Dev Immunol       Date:  2012-05-09

Review 3.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

4.  Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.

Authors:  Bobbie Ann Austin; Cassandra M James; Peter Härle; Daniel J J Carr
Journal:  Biol Proced Online       Date:  2006-06-14       Impact factor: 3.244

5.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.